Key Financials for Q2 FY2025-26 (Ended September 30, 2025):

• Net Profit: ₹25.14 crore, up 76.4% YoY from ₹14.25 crore.
• Revenue from Operations: ₹242.4 crore, up 23.2% YoY from ₹196.7 crore, supported by strong demand across key segments.
• EBITDA: ₹48.34 crore, up 51.8% YoY from ₹31.85 crore.
• EBITDA Margin: Improved to 19.94% from 16.19% YoY, reflecting better cost efficiencies and a stronger product mix.

Fund Utilisation Update:
In a separate filing, SMS Pharmaceuticals confirmed there was no deviation in the utilisation of funds raised via a preferential issue. The company had allotted 90 lakh convertible warrants in March 2024, converted into equity shares in two tranches—40 lakh in March 2025 and 50 lakh in September 2025—after receiving 75% of the issue price.

The funds were primarily deployed for:

• Capacity expansion
• Backward integration of key starting materials
• Working capital requirements

Market Response:

• SMS Pharma shares rose 1.8% on Friday, November 7, 2025.
• The stock has gained nearly 13% year-to-date.

The strong quarterly performance highlights SMS Pharmaceuticals’ robust growth trajectory, driven by operational efficiency and strategic use of funds for expansion and integration.